Inositol augmentation of lithium or valproate for bipolar depression

Bipolar Disorders

Volumn 8, Issue 2, 2006, Pages 168-174

  Evins, A Eden ^a   Demopulos, Christina ^a   Yovel, Iftah ^a   Culhane, Melissa ^a   Ogutha, Jacqueline ^a   Grandin, Louisa D ^a   Nierenberg, Andrew A ^a   Sachs, Gary S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Affective disorder; Bipolar disorder; Depression; Inositol; Lithium; Second messenger; Valproate

Indexed keywords

INOSITOL; LITHIUM; PLACEBO; VALPROIC ACID;

ADULT; AGGRESSION; ANGER; ARTICLE; BIPOLAR DEPRESSION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DISRUPTIVE BEHAVIOR; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HAMILTON SCALE; HOSTILITY; HUMAN; IRRITABILITY; MALE; MANIA; OPEN STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SYMPTOMATOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INOSITOL; LITHIUM CARBONATE; MALE; MIDDLE AGED; QUESTIONNAIRES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; VALPROIC ACID;

EID: 33745843334     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2006.00303.x     Document Type: Article

References (33)

1. Weissman MM, Leaf PJ, Tischler GL et.al. Affective disorders in five United States communities. Psychol Med 1988; 18: 141-153.
2. Kessler RC, McGonagle KA, Zhao S et.al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19.
3. Coppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P, Hermon C. Long-term lithium and mortality. Lancet 1990; 335: 1347.
4. Small JG, Klapper MH, Milstein V, Marhenke JD, Small IF. Comparison of therapeutic modalities for mania. Psychopharmacol Bull 1996; 32: 623-627.
5. Calabrese JR, Kimmel SE, Woyshville MJ et.al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153: 759-764.
6. Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992; 32: 270-280.
7. Green AI, Tohen M, Patel JK et.al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000; 157: 982-986.
8. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215-236.
9. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152: 1635-1640.
10. Baraban JM, Worley PF, Snyder SH. Second messenger systems and psychoactive drug action: Focus on the phosphoinositide system and lithium. Am J Psychiatry 1989; 146: 1251-1260.
11. Barkai AI, Dunner DL, Gross HA, Mayo P, Fieve RR. Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol Psychiatry 1978; 13: 65-72.
12. Levine J, Kurtzman L, Rapoport A et.al. CSF inositol does not predict antidepressant response to inositol. J Neural Transm 1996; 103: 1457-1462 (Short communication).
13. Coupland NJ, Ogilvie CJ, Hegadoren KM, Seres P, Hanstock CC, Allen PS. Decreased prefrontal myo-inositol in major depressive disorder. Biol Psychiatry 2005; 57: 1526-1534.
14. Atack JR, Levine J, Belmaker RH. Cerebrospinal fluid inositol monophosphatase: Elevated activity in depression and neuroleptic-treated schizophrenia. Biol Psychiatry 1998; 44: 433-437.
15. Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JE. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry 1997; 154: 1148-1150.
16. Wolfson M, Bersudsky Y, Zinger E, Simkin M, Belmaker RH, Hertz L. Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. Brain Res 2000; 855: 158-161.
17. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2; 417: 292-295.
18. Cheng L, Lumb M, Polgar L, Mudge A. How can the mood stabilizer VPA limit both mania and depression? Mol Cell Neurosci 2005; 29: 309-326.
19. Levine J, Rapaport A, Lev L et.al. Inositol treatment raises CSF inositol levels. Brain Res 1993; 627: 168-170.
20. Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol 2001; 21: 335-339.
21. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995; 152: 1084-1086.
22. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996; 153: 1219-1221.
23. Levine J, Barak Y, Gonzalves M et.al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995; 152: 792-794.
24. Chengappa KN, Levine J, Gershon S et.al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord 2000; 2: 47-55.
25. Mottram P, Wilson K, Copeland J. Validation of the Hamilton Depression Rating Scale and Montgomery and Åsberg Rating Scales in terms of AGECAT depression cases. Int J Geriatr Psychiatry 2000; 15: 1113-1119.
26. Leung CM, Wing YK, Kwong PK, Lo A, Shum K. Validation of the Chinese-Cantonese version of the Hospital Anxiety and Depression Scale and comparison with the Hamilton Rating Scale of Depression. Acta Psychiatr Scand 1999; 100: 456-461.
27. Brannan SK, Mallinckrodt CH, Detke MJ, Watkin JG, Tollefson GD. Onset of action for duloxetine 60 mg once daily: Double-blind, placebo-controlled studies. J Psychiatr Res 2005; 39: 161-172.
28. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24: 389-399.
29. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
30. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS). Psychol Rep 1962; 10: 799-812.
31. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
32. Levine J, Schooler NR. SAFTEE: A technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986; 22: 343-381.
33. Cheng L, Lumb M, Polgar L, Mudge A. How can the mood stabilizer VPA limit both mania and depression? Mol Cell Neurosci 2005; 29: 309-326.